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Abstract
Introduction In contrast to nonsteroidal aromatase inhibitors,
the steroidal aromatase inactivator exemestane does not have
detrimental effects on bone in animal models. This study was
designed to compare the effects of exemestane with the
nonsteroidal aromatase inhibitors anastrozole and letrozole on
serum and urine levels of biomarkers of bone turnover in healthy
postmenopausal women.
Methods Changes in the concentrations of bone-turnover
markers, estrogens, and lipids were assessed after daily
administration of exemestane (25 mg), letrozole (2.5 mg),
anastrozole (1 mg), or placebo for 24 weeks in healthy
postmenopausal women. The primary end point was the
percentage change from baseline in bone-turnover-marker
levels at week 24. The baseline-adjusted area under the curve
(AUC) for weeks 0–12 and 0–24 was calculated to evaluate
changes in bone turnover over time, rather than at discrete time
points.
Results Seventy-four (88%) of 84 randomized subjects were
evaluable for bone-marker assays. Reductions in plasma
estrogen levels and increases in bone-resorption markers were
comparable for each aromatase inhibitor. Uniquely, exemestane
consistently increased the percentage change from baseline in
the level of serum procollagen type I N-terminal propeptide
(PINP), a marker of bone formation, at week 24. In the active-
treatment groups, the baseline-adjusted AUC at weeks 0–12
and 0–24 for PINP was significantly greater for exemestane than
the other aromatase inhibitors.
Conclusion Exemestane increased serum levels of the bone-
formation marker PINP after 24 weeks, suggesting a specific
bone-formation effect related to its androgenic structure.
Potential effects on cortical bone and reduced fracture risk must
be verified in a comparative clinical trial.
Introduction
Aromatase inhibitors (AIs), which potently suppress estrogen
synthesis in postmenopausal women, are increasingly used in
the treatment of early-stage breast cancer to prevent disease
recurrence. AIs reduce the plasma estrogen concentration by
suppressing peripheral estrogen synthesis and might also
suppress estrogen synthesized locally by aromatase in bone
[1]. Because osteoporosis and the concomitant fracture risk
are potentially serious adverse effects of AIs, a better under-
standing of their effects on bone is necessary.
Two classes of AIs, nonsteroidal and steroidal, are currently
used in the treatment of breast cancer patients. After 1 year of
treatment, the nonsteroidal AI anastrozole was reported to
increase markers of bone turnover by 12.2–20.8% in post-
menopausal women who had early breast cancer [2]. In the
same study, after 1 and 2 years, anastrozole induced
decreases of 2.6% and 4.0%, respectively, in lumbar spine
bone mineral density (BMD) and 1.7% and 3.2%, respectively,
in total hip BMD [3]. The nonsteroidal AI letrozole has similar
effects. In a study in healthy late-postmenopausal women,
letrozole increased markers of bone turnover by 15% after 6
months [4], and in a similar study, there was a 25% increase
in a marker of bone resorption after 3 months of letrozoleBreast Cancer Research    Vol 9 No 4    Goss et al.
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treatment [5]. Preliminary results from a large, multicenter,
open-label trial demonstrated that after 1 year of treatment
with letrozole, lumbar spine and total hip BMDs decreased by
2.6% and 2.1%, respectively [6].
In a preclinical model, the steroidal aromatase inactivator
exemestane showed no detrimental effects on markers of
bone turnover or BMD. Moreover, exemestane was protective
against bone loss that occurred following ovariectomy in rats,
whereas letrozole was not [7]. In the clinical setting, postmen-
opausal women with early breast cancer treated using
exemestane (25 mg daily) or placebo for 2 years experienced
a mean annual bone loss of 2.2% vs 1.8% (P = 0.57), respec-
tively, in the lumbar spine and 2.7% vs 1.5% (P = 0.024),
respectively, in the femoral neck. Exemestane also significantly
increased levels of biomarkers for bone resorption and forma-
tion [8]. Because of the lack of any significant difference in the
change in BMD in the lumbar spine, an area with frequent
compression fractures, the clinical implication of a 1.2% (90%
confidence interval (CI), 0.3–2.1%) difference in femoral neck
BMD between the exemestane-treated group and the placebo
group has been questioned [9]. Although these data support
the possibility that exemestane might be associated with an
attenuation of bone loss, they do not fully resolve questions
regarding the role or mechanism of exemestane in bone
turnover.
Other clinical studies have also reported unfavorable bone
effects of exemestane, anastrozole, and letrozole [10-15],
including an increased risk of fractures using anastrozole [16]
and exemestane [14] compared with tamoxifen. However, the
prior administration of tamoxifen – which is bone protective –
in several of these studies makes interpretation of these find-
ings difficult.
To date, there are no comparative data on the effects of the dif-
ferent AIs on bone. This study was conducted to compare the
effects of the steroidal AI exemestane with the nonsteroidal
AIs anastrozole and letrozole or placebo on serum and urine
levels of biomarkers of bone turnover in healthy postmenopau-
sal women.
Materials and methods
This randomized, single-blind, placebo-controlled exploratory
study investigated the effect of low plasma estrogen levels,
induced by AIs, on markers of bone turnover in 80 healthy
postmenopausal women during 24 weeks of outpatient treat-
ment using exemestane, letrozole, anastrozole, or placebo. All
patients provided written informed consent. The study was
conducted at two sites in Germany in accordance with the eth-
ical principles that originated in the Declaration of Helsinki.
Patient selection and treatment
Healthy postmenopausal volunteers between 50 and 75 years
of age were enrolled. Eligible subjects were at least 1 year
postmenopause (defined as no menstrual bleeding for at least
1 year before screening and documented luteinizing and folli-
cle-stimulating hormone levels within the postmenopausal
range), had a body-mass index of 19–35 kg/m2, and had a
body weight of 55–95 kg. All subjects had a normal BMD for
their age, as confirmed by quantitative ultrasonometry (QUS).
Exclusion criteria included current or previous use of bisphos-
phonates or any other drug known to affect bone metabolism
(including hormone-replacement therapy and statins) within 1
month before study entry, use of any medication within 2
weeks or five half-lives of the medication (whichever was
longer) before study entry, subclinical hyperthyroidism or other
metabolic disorder, any form of osteoporosis (as measured by
BMD or QUS testing), and a history of bilateral oophorectomy.
Eligible subjects were randomized 1:1:1:1 to receive 24
weeks of treatment with anastrozole (1 mg), exemestane (25
mg), letrozole (2.5 mg), or placebo. Placebo tablets were iden-
tical in appearance to exemestane. Each treatment was admin-
istered orally, once daily after breakfast. Follow-up was
continued until 12 weeks after the last dose of study medica-
tion (36 weeks).
Study end points
Subjects were evaluated at baseline and 2, 4, 8, 12, 16, 20,
24, and 36 (follow-up) weeks. At each visit, clinical and labo-
ratory safety tests were performed and blood and urine sam-
ples were obtained for assessment of the study end points.
The primary study end point was the percentage change from
baseline to week 24 in bone-turnover biomarkers, including
bone-formation markers (bone alkaline phosphatase (BAP)
and procollagen type I N-terminal propeptide (PINP)) and
bone-resorption markers (serum C-terminal telopeptide of
type I collagen (S-CTx), urine-adjusted urinary (U-)CTx, and
urine-adjusted urinary N-terminal telopeptide of type I collagen
(U-NTx)).
Predefined secondary end points included the percentage
change from baseline in concentrations of bone-turnover
biomarkers at weeks 12 and 36 (12 weeks after completion of
treatment), change in the baseline-adjusted area under the
curve (AUC) for weeks 0–12 and 0–24 for bone-turnover
markers, percentage of baseline estrogen concentrations
(estradiol (E2), estrone (E1), and estrone sulfate (E1S)) at
weeks 12, 24, and 36, percentage change from baseline in
lipid parameters (total cholesterol, low-density lipoprotein cho-
lesterol, high-density lipoprotein cholesterol, and triglycerides)
at weeks 12, 24, and 36, and safety.
Adverse events were monitored by means of verbal probes
and spontaneous reports and reported using the National
Cancer Institute Common Toxicity Criteria (NCI CTC) medical
terminology and grading system, version 2.0. PatientsAvailable online http://breast-cancer-research.com/content/9/4/R52
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experiencing adverse events that were considered to be caus-
ally related to study medication were followed up until resolu-
tion of the event.
Sample collection and handling
Blood and urine samples were obtained at baseline and 2, 4,
8, 12, 16, 20, 24, and 36 (follow-up) weeks. Blood samples
for estrogen measurement were collected into prechilled
heparinized tubes. Baseline levels were defined as the mean
of observations taken on study days -2, -1, and 0. Subjects
were instructed to consume nothing by mouth after midnight
on the day before scheduled visits.
Serum was harvested from blood samples, which were drawn
in the morning before drug dosing and after an overnight fast.
Second-void urine samples were collected in the morning
before dosing and after an overnight fast. Serum, plasma, and
urine samples were stored at -20°C until processed.
Laboratory methods
All assays were performed in centralized laboratories under
blinded conditions. Assays for CTx and NTx were performed
on urine samples. Urinary assay values were corrected for uri-
nary dilution by urinary creatinine analysis [17]. U-CTx and U-
NTx levels were adjusted for renal function according to the
level of urinary creatinine. Concentrations of BAP, CTx, PINP,
and lipids were measured in serum samples. Estrogen levels
were measured in plasma. The levels of bone-turnover mark-
ers, lipids, and estrogens were evaluated by radioimmu-
noassay, ELISA, or automated tests using commercially
available kits as specified by the manufacturers (Table 1). For
the estrogen assays, the radioimmunoassays were performed
on plasma samples previously purified by HPLC to remove any
potential interference by exemestane and its metabolites [18].
Statistical analysis
This was an exploratory study, and no reliable comparable
bone-turnover-marker data are available in this study popula-
tion. The sample size was calculated according to an effect
size, defined as the expected difference in group means to the
within-group standard deviation. A sample size of 20 within
each of the four treatment groups was calculated to have an
80% power to detect an approximate effect size of 0.9 at the
0.05 level. The current analysis was performed in the evaluable
population, which included all randomized subjects who
received at least one dose of study medication, had evaluable
data from the baseline and week 12 assessments at least, and
maintained suppression of estrogen throughout the study.
Descriptive statistics, including mean, standard deviation,
median, and range for continuous variables and frequency and
percentage for categorical variables, were used for all demo-
graphics, baseline characteristics, and pretreatment condi-
tions, as appropriate. Percentage change from baseline in
bone-turnover markers and lipid profiles and percentage of
baseline estrogen concentrations were also summarized by
assessment time and treatment arm using descriptive
statistics. A one-way analysis of variance model was used to
test baseline and demographic characteristics for homogene-
Table 1
Laboratory methods for assay of bone-turnover markers, lipids, and estrogens
Parameter Method Manufacturer
Bone resorption
Adjusted U-CTx Enzyme immunoassay test using the CrossLaps® 
ELISA kit
Nordic Bioscience Diagnostics A/S, Herlev, 
Denmark
S-CTx Electrochemoluminescence immunoassay 
technique using Elecsys 2010 automate analyzer
Roche Diagnostics, Basel Switzerland
Adjusted U-NTx Competitive immunoassay technique using the NTx 
reagent pack kit
Ortho-Clinical Diagnostics, Amersham, UK
Bone formation
BAP Ostase Assay using Access Immunoassay System Beckman Coulter, Villepinte, France
PINP Electrochemoluminescence immunoassay 
technique using Elecsys 2010 automate analyzer
Roche Diagnostics
Lipids (total cholesterol, LDL cholesterol, 
HDL cholesterol, and triglycerides)
Validated HPLC–RIA technique using Bayer Advia 
Reagent Packs. Assayed on an ADVIA® 1650 
chemistry system analyzer
Bayer Diagnostics, Bayer Inc., Tarrytown, NY, 
USA
Estrogen (E1, E2, and E1S) Validated HPLC–RIA technique Aster-Cephac, Paris, France
BAP, bone alkaline phosphatase; E1, estrone; E1S, estrone sulfate; E2, estradiol; ELISA, enzyme-linked immunosorbent assay; HDL, high-density 
lipoprotein; HPLC–RIA, high-performance liquid chromatography radioimmunoassay; LDL, low-density lipoprotein; PINP, procollagen type I N-
terminal propeptide; S-CTx, serum C-terminal telopeptide of type I collagen; U-CTx, urine-adjusted urinary C-terminal telopeptide of type I 
collagen; U-NTx, urine-adjusted urinary N-terminal telopeptide of type I collagen.Breast Cancer Research    Vol 9 No 4    Goss et al.
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ity of the populations in each of the four treatment groups. The
Kruskall–Wallis test was used to exclude differences in the
baseline values of bone-turnover markers, plasma estrogen
concentrations, and lipid profiles between the three active
treatment groups and compare the percentage change in
these parameters from baseline. Values reported as below the
limit of quantification for markers of bone turnover (<2 for cre-
atinine and ≤28 for U-NTx) were treated as missing data.
The baseline-adjusted AUC (henceforth referred to as AUC for
weeks 0–12 and 0–24 was calculated for all bone-turnover
markers to evaluate accumulated changes in bone turnover
over time, rather than at discrete time points [19]. The AUC
was calculated as follows, using BAP as an example: the base-
line-adjusted AUC0-t week was calculated as the AUCBAP-t*
baseline concentration of BAP, where t = 12 or 24 weeks. The
AUCBAP(0-t) was then calculated by summing the partial AUCs
using the trapezoidal rule. The AUC was summarized by
assessment time and treatment arm by means of descriptive
statistics.
Results
One hundred and seventy-five subjects were screened. A total
of 84 subjects were randomized to one of four treatment
groups and included in the safety evaluation. All randomized
subjects received at least one dose of study medication. Estro-
gen and lipid levels were reported in the modified intent-to-
treat (mITT) population (n = 79), which excluded five subjects
who discontinued treatment early owing to withdrawal of con-
sent (one anastrozole- and two exemestane-treated subjects)
and adverse events (one placebo- and one anastrozole-
treated subject). Estrogen levels were not suppressed in five
subjects (one exemestane-, one letrozole-, and three anastro-
zole-treated subjects). Estrogen levels returned to baseline
values after initial suppression to below the limit of quantifica-
tion in two additional subjects who were presumed to be non-
compliant. Because the intent of the study was to assess
differences among AIs in the presence of low plasma levels of
estrogen, these subjects were excluded from the bone-marker
analyses; therefore, the evaluable population for bone-marker
data from baseline comprised 74 subjects. Bone-marker data
for the two additional subjects were excluded from the analysis
from the time the estrogen levels increased (weeks 16 and 20,
respectively). Patient disposition is summarized in Figure 1.
Baseline characteristics were comparable among the four
treatment groups in the safety and mITT populations. Baseline
demographics for the evaluable population are summarized in
Table 2. All subjects were white women who had experienced
a natural menopause; no subjects had undergone ovariec-
tomy. The overall mean (standard deviation) time since the
onset of menopause was 11.7 (6.7) years (range, 1–28 years).
Baseline concentrations of bone-turnover markers, estrogens,
and lipids were similar among the treatment groups (Table 2).
Bone turnover
Baseline concentrations of bone-turnover markers in the eval-
uable population were similar among the treatment groups
(Table 2). The effects of each treatment on bone-turnover
markers are summarized in Table 3.
Bone-formation markers
For the primary end point of the percentage increase from
baseline of PINP concentration at 24 weeks, exemestane
treatment demonstrated an approximately fourfold greater
increase from baseline compared with the other AIs and pla-
cebo (Figure 2). Because the magnitude of this change was of
interest, a retrospective statistical comparison among treat-
ment arms using a nonparametric Kruskall–Wallis test was
performed. The results of this analysis demonstrated that, at
24 weeks, only exemestane treatment consistently resulted in
an increase in the level of PINP, with a median percentage
change of 24% and 95% CI of 11–30% (Table 3); however,
between-group differences did not reach statistical signifi-
cance at 24 weeks (P = 0.147). At week 36, 12 weeks after
discontinuation of treatment, the percentage change from
baseline was positive for the three AIs, by approximately 24%
for letrozole, 15% for exemestane, and 10% for anastrozole,
compared with a slight decrease from baseline for placebo.
Subjects receiving exemestane exhibited a significantly higher
baseline-adjusted AUC for PINP during treatment. Because
the differences were significant overall among the four groups
(P = 0.011 for AUC0–12 week and P = 0.004 for AUC0–24 week),
pairwise comparisons were assessed, as above. The AUC0–12
week for subjects receiving exemestane was elevated (42%;
95% CI, 25–73%) from baseline, whereas the letrozole- and
anastrozole-treated groups showed a decrease of approxi-
mately 10% from baseline (P = 0.002 and P = 0.011 for letro-
zole or anastrozole vs exemestane, respectively); the placebo
group showed an increase of approximately 19%. The AUC0–
24 week for exemestane was dramatically greater (187%; 95%
CI, 95–295%) than that observed for both nonsteroidal AIs (P
< 0.001 and P = 0.004 for letrozole or anastrozole vs exemes-
tane, respectively). Because the magnitude of this change was
also of interest, a retrospective statistical comparison, as
described above, was again used to compare results between
treatment arms (Figure 3).
The median percentage change in BAP concentration at week
24 in the exemestane-treated group was increased slightly
from baseline, whereas other treatment groups exhibited slight
decreases in the concentration of BAP from baseline (Figure
4); however, the 95% CI for exemestane was nearly twice that
of the other groups at this time point (Table 3). At week 12, all
groups exhibited a slight decrease in the concentration from
baseline, with anastrozole demonstrating the largest
decrease. At week 36, the percentage change in BAP concen-
tration from baseline in the letrozole-treated group was more
than twofold compared with the exemestane-treated groupAvailable online http://breast-cancer-research.com/content/9/4/R52
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and more than tenfold compared with the anastrozole-treated
or placebo groups.
For the AUC0–12 week and the AUC0–24 week, the subjects
receiving exemestane were the only group to exhibit an
increase from baseline (except the placebo group at 24
weeks); in the other two AI-treated groups, the AUC0–12 week
decreased approximately 4% from baseline and the AUC0–24
week decreased approximately 14% from baseline. Patients
administered placebo demonstrated a slight decrease from
baseline in the AUC0–12 week and their AUC0–24 week was essen-
tially unchanged from baseline.
Figure 1
Patient disposition Patient disposition.
(n=19) (n=19) (n=16) (n=20)
Randomized
n=84
Allocated to Exemestane
(n=22)
Allocated to Letrozole
(n=20)
Allocated to Anastrozole
(n=21)
Allocated to Placebo
(n=21)
Discontinued (n=2)
Withdrew Consent 2
Adverse Events 0
Discontinued (n=0)
Withdrew Consent 0
Adverse Events 0
Discontinued(n=2)
Withdrew Consent 1
Adverse Events 1
Discontinued(n=1)
Withdrew Consent 0
Adverse Events 1
Excluded From Analysis 
Because of a Lack of
Suppression of Estrogen 
Levels (n=1)
Excluded From Analysis 
Because of a Lack of
Suppression of Estrogen
Levels (n=1)
Excluded From Analysis 
Because of a Lack of
Suppression of Estrogen 
Levels(n=3)
Excluded From Analysis 
Because of a Lack of
Suppression of Estrogen 
Levels(n=0)
Evaluable
(n=19)
Evaluable
(n=19)
Evaluable
(n=16)
Evaluable
(n=20)
Evaluated
N=175Breast Cancer Research    Vol 9 No 4    Goss et al.
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Bone-resorption markers
For S-CTx, the median percentage change from baseline
increased at week 24 with exemestane and letrozole treat-
ment, demonstrating approximately twofold greater increases
compared with anastrozole treatment or placebo. These
increases were already apparent at week 12, and the increase
from week 12 to week 24 was less noticeable. At week 36, the
median percentage change from baseline for S-CTx was
essentially unchanged from week 24 for the groups receiving
letrozole, anastrozole, and placebo, but that of the exemes-
Table 2
Baseline characteristics and baseline bone turnover values in the safety population
Mean (SD)
Median (min., max.)
Parameter Exemestane (n = 22) Letrozole (n = 20) Anastrozole (n = 21) Placebo (n = 21)
Baseline characteristics
Age, years 61 (4.7)
61 (52, 72)
60 (4.7)
60 (47, 69)
57 (5.1)
56 (50, 64)
59 (4.2)
60 (52, 65)
Weight, kg 69 (7.5)
70 (56, 85)
72 (9.4)
70 (59, 95)
66 (7.4)
68 (55, 83)
72 (13)
73 (45, 102)
Height, cm 165 (6.4)
165 (156, 178)
162 (4.7)
163 (149, 170)
163 (5.0)
163 (154, 172)
164 (4.5)
164 (155, 173)
BMI, kg/m2 26 (2.8)
25 (21, 32)
27 (3.5)
28 (22, 35)
25 (2.9)
24 (20, 32)
27 (4.8)
27 (18, 38)
Time since menopause, 
years
13 (8.1)
12 (1.0, 28)
12 (7.4)
9.0 (3.0, 25)
12 (6.6)
8.5 (4.0, 25)
10 (5.3)
10 (3.0, 21)
Baseline bone-turnover values*
BAP, ng/ml 16 (7.8)
13 (7.4, 38)
12 (3.3)
11 (6.1, 19)
16 (5.4)
16 (6.8, 25)
14 (3.7)
14 (5.4, 19)
S-CTx, ng/ml 0.51 (0.21)
0.49 (0.23, 0.94)
0.39 (0.12)
0.41 (0.18, 0.59)
0.54 (0.16)
0.58 (0.21, 0.79)
0.41 (0.14)
0.39 (0.16, 0.66)
PINP, ng/ml 57 (25)
55 (21, 106)
44 (12)
41 (25, 74)
53 (20)
51 (13, 92)
48 (19)
45 (23, 96)
U-CTx, μg/mmol Cr 289 (143)
237 (140, 725)
234 (66)
242 (112, 358)
338 (98)
322 (133, 550)
256 (68)
241 (174, 383)
U-NTx, nmol
BCE/mmol Cr
61 (31)
55 (19, 140)
53 (16)
55 (27, 85)
66 (24)
63 (40, 128)
61 (22)
54 (27, 103)
Baseline estrogen concentrations (pg/ml)
E1 34 (15)
31 (11, 72)
30 (11)
28 (13, 51)
31 (12)
28 (14, 61)
30 (11)
27 (10, 61)
E2 4.7 (2.5)
4.4 (1.1, 13)
4.8 (2.1)
4.2 (1.8, 8.6)
6.3 (7.0)
3.9 (1.9, 32)
4.5 (2.1)
3.9 (1.9, 9)
E1S Estrone sulfate 221 (150)
189 (58, 757)
269 (222)
193 (79, 1075)
252 (199)
197 (64, 896)
274 (249)
211 (62, 1156)
Baseline lipid concentrations (mmol/L)
Total cholesterol 5.9 (0.70)
6 (5, 7)
6.1 (0.65)
6 (5, 8)
6.2 (0.82)
6 (4, 8)
5.8 (0.73)
6 (4, 8)
LDL cholesterol 4 (0.8)
4 (2, 6)
4 (0.9)
4 (3, 7)
4 (0.8)
4 (3, 6)
4 (0.7)
4 (2, 6)
HDL cholesterol 1.5 (0.41)
1.4 (0.90, 2.6)
1.5 (0.43)
1.5 (0.87, 2.2)
1.4 (0.39)
1.4 (0.83, 2.4)
1.5 (0.31)
1.4 (1.1, 2.3)
Triglycerides 1.4 (0.81)
1.1 (0.67, 3.7)
1.3 (0.44)
1.2 (0.72, 2.2)
1.3 (0.48)
1.2 (0.54, 2.5)
1.1 (0.42)
1.0 (0.52, 2.1)
*The baseline value was calculated as the mean of three baseline measurements.
BAP, bone alkaline phosphatase; BCE, bone collagen equivalent; BMI, body-mass index; Cr, creatinine; E1, estrone; E1S, estrone sulfate; E2, 
estradiol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; max; min; PINP, procollagen type I N-terminal peptide; S-CTx, serum C-
terminal telopeptide of type I collagen; SD, standard deviation; U-CTx, urine C-terminal telopeptide of type I collagen; U-NTx, urine N-terminal 
telopeptide of type I collagen.Available online http://breast-cancer-research.com/content/9/4/R52
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tane-treated group decreased by approximately 35% follow-
ing the end of treatment at week 24.
The median percentage changes in the AUC0–12 week and
AUC0–24 week for S-CTx were minimal for all groups.
For the median percentage change in U-CTx at week 24, the
letrozole-treated group had the largest increase from baseline
and 95% CI (34%; 95% CI, 19–74%). Exemestane treatment
and placebo increased the level of U-CTx approximately 22%
and 15%, respectively, and anastrozole treatment demon-
strated only a slight increase (2%; 95% CI, -6% to 29%). By
Table 3
Summary of primary and secondary efficacy results for bone-turnover markers in the evaluable population
Bone-turnover marker Exemestane (n = 19) Letrozole (n = 19) Anastrozole (n = 16) Placebo (n = 20)
Primary efficacy measure: percentage change from baseline to week 24*
BAP 3.0 (-11, 24) -0.58 (-9.4, 7.1) -4.5 (-7.0, 4.5) -0.88 (-11.8, 8.1)
S-CTx 21 (6.9, 34) 31 (12, 69) 9.3 (-7.7, 34) 12 (-8.7, 26)
PINP 24 (11, 30) 5.7 (-1.1, 12) 6.3 (-9.3, 19) 6.1 (-11, 16)
U-CTx 22 (10, 35) 34 (19, 74) 1.7 (-5.6, 29) 15 (1.5, 29)
U-NTx -8.5 (-30, 1.9) 10 (-1.5, 20) -1.5 (-26, 24) 1.7 (-13, 19)
Secondary efficacy measure: percentage change from baseline to week 12*
BAP -1 (-5.7, 8.0) -4.3 (-7.5, 7.3) -7.3 (-17, 3.7) -0.99 (-6.0, 3.3)
S-CTx 18 (10, 37) 18 (7.2, 39) 8.0 (-9.6, 22) 8.3 (2.9, 19)
PINP 19 (-1.1, 34) -0.29 (-5.9, 7.2) 0.92 (-7.4, 7.1) 4.1 (-12, 21)
U-CTx 20 (4.7, 38) 14 (8.4, 24) 2.9 (-13, 9.0) 8.8 (2.0, 13)
U-NTx 6.8 (1.1, 23) 0.21 (-12, 4.2) -2.3 (-15, 22) -0.36 (-13, 19)
Secondary efficacy measure: percentage change from baseline to week 36*
BAP 5.6 (3.7, 26) 15 (1.7, 29) 1.4 (-6.3, 6.6) -1.9 (-10, 6.9)
S-CTx 13 (-2.2, 34) 30 (22, 52) 9.2 (-13.5, 22) 13 (1.2, 19)
PINP 15 (-0.14, 39) 24 (-0.33, 56) 10 (0.47, 25) -0.92 (-16, 22)
U-CTx 17 (-5.8, 43) 46 (26, 70) 7.4 (-28, 29) 23 (1.1, 39)
U-NTx -6.3 (-20, 5.1) 11 (-1.3, 34) -1.4 (-14, 46) 6.5 (-6, 26)
Secondary efficacy measure: AUC0–12 week*
BAP, ng/ml × week 1.6 (-2.0, 10) -3.7 (-8.6, 2.3) -5.8 (-26, 3.2) -1.7 (-9.0, 5.7)
S-CTx, ng/ml × week 0.68 (0.52, 1.37) 0.60 (0.28, 0.99) 0.33 (-0.28, 0.73) 0.38 (0.085, 0.65)
PINP, ng/ml × week 42 (25, 73) -10 (-47, 23) -11 (-31, 20) 19 (-24, 56)
U-CTx(adjusted), μg/mmol 
Cr × week
269 (-173, 553) 302 (53, 643) -242 (-762, 192) 105 (-129, 396)
U-NTx(adjusted), nmol 
BCE/mmol Cr × week
49 (-2.4, 91) 50 (15, 81) -6.5 (-49, 30) 0.67 (-92, 42)
Secondary efficacy measure: AUC0–24 week*
BAP, ng/ml × week 17 (-3.7, 29) -14 (-23, 8.1) -14 (-55, 9.2) 0.31 (-26, 12)
S-CTx, ng/ml × week 2.0 (1.3, 2.9) 1.5 (1.1, 2.3) 1.0 (-0.41, 1.8) 0.89 (0.046, 1.6)
PINP, ng/ml × week 187 (95, 295) -6.1 (-57, 79) 19 (-46, 90) 42 (-67, 142)
U-CTx(adjusted), μg/mmol 
Cr × week
1063 (170, 1868) 1157 (422, 2314) 61 (-1077, 588) 427 (51, 751)
U-NTx(adjusted), nmol 
BCE/mmol Cr × week
21 (-64, 176) 102 (-49, 210) -9.0 (-204, 158) -47 (-265, 58)
*All data are medians (bias-corrected and adjusted 95% bootstrap confidence interval).
AUC, area under the curve; BAP, bone alkaline phosphatase; BCE, bone collagen equivalent; Cr, creatinine; PINP, procollagen type I N-terminal 
peptide; S-CTx, serum C-terminal telopeptide of type I collagen; U-CTx, urinary C-terminal telopeptide of type I collagen; U-NTx, urinary N-terminal 
telopeptide of type I collagen.Breast Cancer Research    Vol 9 No 4    Goss et al.
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contrast, at week 12, the exemestane-treated group had the
greatest increase from baseline (20%; 95% CI, 5–38%) and
was approximately sevenfold higher than the anastrozole-
treated group, with the letrozole-treated and placebo groups
intermediate. At week 36, U-CTx levels remained highly ele-
vated from baseline in the letrozole-treated group (46%; 95%
CI, 26–70%) and had an additional relative increase of 37%
from the levels observed at the end of treatment. Anastrozole
treatment and placebo demonstrated similar patterns of
increase, with increases from week 24. By contrast, the level
of U-CTx decreased approximately 23% 12 weeks after dis-
continuation of exemestane treatment.
The AUC0–12 week for U-CTx demonstrated large differences
between groups, with increases of approximately 275% in the
exemestane- and letrozole-treated groups, but a decrease of
242% from baseline in the anastrozole-treated group. The pla-
cebo group demonstrated a lesser increase from baseline of
105%. The 95% CIs for all groups were large; the greatest
was in the anastrozole-treated group and the least was in the
placebo group. For the AUC0–24 week, exemestane and letro-
zole treatment demonstrated extremely large increases from
baseline of 1063% and 1157%, respectively, with the group
receiving placebo demonstrating a lesser increase of 427%
and anastrozole treatment producing an increase of 61% from
Figure 2
Change in serum concentrations of PINP from baseline to week 24 in  the evaluable population Change in serum concentrations of PINP from baseline to week 24 in 
the evaluable population. The median percentage change (95% CI) 
from baseline was consistently positive only for exemestane (24%; 
95% CI, 11–30%). The overall differences between the four groups 
were not statistically significant (P = 0.147 using the Kruskall–Wallis 
test). CI, confidence interval; PINP, procollagen type I N-terminal 
propeptide.
Figure 3
Baseline-adjusted AUC0–24 week for serum concentrations of PINP in the  evaluable population Baseline-adjusted AUC0–24 week for serum concentrations of PINP in the 
evaluable population. The increase in baseline-adjusted AUC0–24 week 
for exemestane was 187% (95% CI, 95–295%). The AUC0–24 week for 
exemestane was significantly greater than anastrozole (P = 0.004), 
letrozole (P < 0.001), or placebo (P = 0.033). Changes in baseline-
adjusted AUC0–24 week were not statistically significant for other active 
treatments or placebo. The overall differences between the four groups 
were statistically significant (P = 0.004 using the Kruskall–Wallis test). 
AUC, area under the curve; PINP, procollagen type I N-terminal 
propeptide.
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Figure 4
Change in serum concentrations of BAP from baseline to week 24 in  the evaluable population Change in serum concentrations of BAP from baseline to week 24 in 
the evaluable population. BAP, bone alkaline phosphatase.
Figure 5
Change in U-NTx concentrations from baseline to week 24 in the evalu- able population Change in U-NTx concentrations from baseline to week 24 in the evalu-
able population. UNTx(adjusted), adjusted urinary N-terminal telopeptide 
of type I collagen.
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baseline. The 95% CI for the AUC(0–24 wk) in the placebo group
was approximately half that of the active-treatment groups.
Changes in the levels of U-NTx were variable across groups
and time points. At the primary end point of 24 weeks, letro-
zole treatment increased the level from baseline, exemestane
treatment decreased the level, and anastrozole treatment and
placebo exhibited only slight changes in the level from base-
line (Figure 5). By contrast, at week 12, the median percent-
age change in the level after exemestane treatment was
increased from baseline, anastrozole treatment demonstrated
a slight decrease in the level from baseline, and the level was
essentially unchanged in the letrozole-treated and placebo
groups. Twelve weeks after discontinuation of study drug, the
letrozole-treated and placebo groups again demonstrated
moderate increases in the level of U-NTx from baseline,
whereas the exemestane- and anastrozole-treated groups
exhibited moderate-to-small decreases from the baseline level.
For the AUC(0–12 week), U-NTx was elevated approximately
50% from baseline in the exemestane- and letrozole-treated
groups, decreased approximately 6% from baseline in the
anastrozole-treated group, and remained essentially
unchanged in the placebo group. At 24 weeks, letrozole treat-
ment demonstrated a fivefold greater increase in the AUC(0–24
week) from baseline, compared with exemestane treatment,
whereas the level in the anastrozole-treated group decreased
nearly 10% and that in the placebo group decreased nearly
50% from baseline.
Estrogen plasma concentrations
Baseline concentrations of estrogens in the mITT population
were similar among treatment groups (Table 2). As expected,
estrogen concentrations (E1, E2, and E1S) were significantly
reduced compared with the placebo group at 12 and 24
weeks in the evaluable subjects treated with all three AIs (P <
0.001 for all comparisons; Table 4). The levels of E1 and E2
Table 4
Median values and median percentage change from baseline for plasma concentrations of estrogens (mITT population)
Estrogen Exemestane (n = 20) Letrozole (n = 20) Anastrozole (n = 18) Placebo (n = 20)
E1
Baseline, median (min., max.) 31 (11, 72) 28 (13, 51) 29 (14, 61) 26 (9.9, 61)
Week 12, median (min., max.) 2.0 (1.8, 10) 1.8 (1.8, 20) 1.8 (1.8, 84) 31 (8.4, 58)
% baseline, median (95% CI*) 7.8 (6.9, 9.3) 6.6 (5.5, 8.1) 7.6 (6.4, 11) 101 (89, 110)
Week 24, median (min., max.) 1.8 (1.8, 63) 1.8 (1.8, 33) 1.8 (1.8, 44) 26 (7.2, 56)
% baseline, median (95% CI) 6.7 (5.3, 8.6) 6.6 (5.1, 8.1) 7.9 (7.1, 11) 94 (76, 108)
Week 36, median (min., max.) 23 (10, 62) 19 (10, 44) 25 (8.4, 158) 22 (13, 46)
% baseline, median (95% CI) 72 (63, 86) 76 (61, 93) 70 (66, 121) 89 (72, 95)
E2
Baseline, median (min., max.) 4.4 (1.1, 13) 4.2 (1.8, 8.6) 3.8 (1.9, 32) 3.9 (1.9, 8.8)
Week 12, median (min., max.) 0.70 (0.70, 2.5) 0.70 (0.70, 2.7) 0.70 (0.70, 104) 3.8 (1.6, 15)
% baseline, median (95% CI) 18 (14, 22) 19 (14, 24) 20 (18, 31) 102 (87, 115)
Week 24, median (min., max.) 0.70 (0.70, 29) 0.70 (0.70, 7.3) 0.72 (0.70, 84) 4.4 (1.9, 12)
% baseline, median (95% CI) 19 (13, 22) 18 (13, 24) 22 (19, 31) 128 (95, 139)
Week 36, median (min., max.) 4.5 (1.6, 36) 4.2 (1.9, 15) 4.2 (1.4, 136) 4.0 (1.6, 11)
% baseline, median (95% CI) 103 (89, 134) 109 (81, 119) 106 (92, 130) 105 (90, 130)
E1S
Baseline, median (min., max.) 192 (58, 757) 193 (79, 1075) 202 (64, 896) 200 (62, 1156)
Week 12, median (min., max.) 13 (8.7, 246) 8.7 (6.0, 62) 15 (6.6, 3260) 209 (58, 876)
% baseline, median (95% CI) 9.1 (6.1, 11) 4.5 (3.3, 6.0) 11 (6.7, 13) 110 (91, 146)
Week 24, median (min., max.) 16 (6.1, 839) 10 (6.0, 254) 18 (8.8, 1440) 195 (64, 802)
% baseline, median (95% CI) 11 (7.2, 13) 4.7 (3.0, 7.2) 10 (8.6, 20) 105 (69, 123)
Week 36, median (min., max.) 223 (7.4, 2100) 222 (115, 932) 296 (58, 4890) 205 (68, 864)
% baseline, median (95% CI) 114 (90, 152) 121 (105, 135) 131 (109, 147) 125 (91, 143)
*95% CI, bias-corrected and adjusted 95% bootstrap CI for median.
CI, confidence interval; E1, estrone; E1S, estrone sulfate; E2, estradiol; max; min; mITT, modified intent to treat.Breast Cancer Research    Vol 9 No 4    Goss et al.
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decreased to near or below the level of quantification. At week
36 (12 weeks after completion of active treatment), plasma E1,
E2, and E1S concentrations had returned to near baseline for
the three active-treatment groups and were again similar to
those observed in the placebo group.
Lipid profiles
Baseline concentrations of lipids in the mITT population were
similar among treatment groups (Table 2). Overall, the per-
centage changes from baseline to week 12, 24, or 36 in all the
lipid parameters monitored were similar between groups
(Table 5).
Safety
Treatment-emergent adverse events were reported by 62
(73.8%) subjects, and treatment-related adverse events were
reported by 39 (46.4%) subjects. Most adverse events were
mild to moderate in severity. Five subjects experienced serious
adverse events (two exemestane-, one anastrozole-, and two
placebo-treated subjects), none of which were considered
related to the study medication. Two subjects (one anastro-
zole- and one placebo-treated subject) discontinued treatment
owing to adverse events, neither of which was considered to
be treatment related. The most frequently reported adverse
events (>10% of subjects in any treatment group) were head-
ache, alopecia, nasopharyngitis, hot flushes, weight increase,
arthralgia, and diarrhea. The incidence of adverse events prob-
ably owing to estrogen reduction was comparable between
treatment groups.
The incidence of laboratory toxicities was comparable
between active-treatment groups and the placebo group. No
laboratory abnormality exceeded NCI CTC toxicity grade 2
(moderate). Most of the laboratory abnormalities were grade 1
(mild), and none were considered an adverse event or clinically
significant by the investigator.
Discussion
In postmenopausal women with early breast cancer, AIs offer
significant benefit over standard treatment with tamoxifen for 5
years in terms of disease-free survival and, for anastrozole and
exemestane, reduced contralateral breast cancer and time to
recurrence [20-25]. Despite these encouraging results, the
long-term clinical impact of AIs must be established because
the aromatase enzyme has an important role in numerous nor-
mal physiological processes [26]. A key role of aromatase is
Table 5
Median values and median percentage change from baseline for serum lipid profiles (mITT population)
Lipid Exemestane (n = 20) Letrozole (n = 20) Anastrozole (n = 19) Placebo (n = 20)
LDL-C (mmol/L)
Baseline 4.2 4.2 4.2 3.8
Week 12, % change -11 -4.5 -12 -6.1
Week 24, % change -2.6 -4.2 -3.0 2.4
Week 36, % change 1.9 0.25 -5.7 -5.8
HDL-C (mmol/L)
Baseline, median 1.4 1.5 1.4 1.4
Week 12, % change -4.4 9.0 1.7 -3.5
Week 24, % change -13 -2.4 -4.4 -6.3
Week 36, % change -6.9 -2.4 -2.5 -6.8
Total cholesterol (mmol/L)
Baseline, median 6.1 6.1 6.3 5.9
Week 12, % change -6.8 -1.8 -3.7 -2.6
Week 24, % change 0.78 1.2 -0.68 0.75
Week 36, % change 1.3 -1.9 -5.8 -6.4
Triglycerides (mmol/L)
Baseline, median 1.1 1.2 1.2 1.0
Week 12, % change -21 6.6 -10 -1.6
Week 24, % change 1.7 4.6 6.3 -7.0
Week 36, % change -1.1 -5.4 -3.5 -0.28
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; mITT = modified intent to treat.Available online http://breast-cancer-research.com/content/9/4/R52
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local production of estrogens, which are essential for the
maintenance of bone integrity [27]. There are, therefore, two
important questions that must be addressed, as follows: will
AIs accelerate the negative skeletal balance associated with
the menopause; and if so, to what extent? Although several rel-
atively short-term clinical studies suggest that AIs accelerate
bone loss [2,4-6,8], to date there have been no comparative
clinical studies. Because preclinical data suggest that the ster-
oidal AI exemestane might have different effects on bone com-
pared with the nonsteroidal AIs [28], this study was designed
to assess the effects of the different AIs by evaluating changes
in bone biomarkers after short-term treatment (24 weeks).
This short-term study demonstrates differential effects of the
AIs evaluated on bone-turnover markers. For the primary end
point of the effect on markers of bone turnover at 24 weeks,
markers of bone resorption were increased in all treatment
groups, including placebo, but the magnitude of increase was
noticeably lower for anastrozole compared with the other
groups. Measures of bone resorption (that is to say, S-CTx and
U-CTx) were increased to the greatest extent by letrozole;
however, the 95% CIs overlapped between all groups. By
contrast, exemestane was the only AI to increase the median
percentage change from baseline to week 24 for both PINP
and BAP concentrations. Although the PINP concentration
was increased from baseline by approximately 6% in all other
groups, the BAP concentration decreased from baseline or
remained essentially unchanged. A retrospective statistical
comparison of the changes in PINP levels showed a statisti-
cally greater increase for exemestane treatment compared
with the other AIs or placebo at week 24, but this statistical
comparison must be interpreted in light of its retrospective
nature and the potential lack of sufficient power of this small
study.
Following discontinuation of treatment at 24 weeks, the levels
of markers of bone resorption (S-CTx and U-CTx) remained
elevated or continued to increase from baseline to week 36 in
patients receiving letrozole, anastrozole, or placebo; by
contrast, the levels of markers of bone resorption tended to
decline towards baseline at week 36 following discontinuation
of exemestane at week 24. The effect of exemestane
withdrawal for 3 and 6 months has been studied in
postmenopausal women following 2 years' treatment [29].
After exemestane withdrawal, bone-resorption markers
returned to, or below, baseline values within 6 months, with the
exception of the S-CTx concentration. For markers of bone for-
mation (for example, BAP, PINP, and osteocalcin), a succes-
sive decrease in values at 3 and 6 months after terminating
therapy was recorded; however, the levels of all markers of
bone formation remained elevated at 6 months compared with
the baseline value. The results of the current study, described
after 12 weeks of exemestane withdrawal, are consistent with
these observations. These findings could be further assessed
by correlating BMD measurements and fracture data to
changes in bone biomarkers in a large confirmatory trial.
The primary benefit of the use of biochemical markers is their
ability to reflect small changes in bone formation or resorption
before such changes are detectable radiologically [30].
Although bone-turnover data are typically reported at discrete
time points, we suggest that assessing data over time using
the AUC method might be more illustrative of the true impact
of interventions. This technique avoids the oversimplification
associated with reporting a value at a single point in time,
which might lead to incorrect inferences. Instead, the AUC
provides a view of the whole spectrum of values because
results are depicted over time [19,30,31].
In our study, the data gathered by the AUC analysis demon-
strate that exemestane might have a greater effect on bone for-
mation compared with the nonsteroidal AIs, particularly PINP
levels. By contrast, letrozole, the more potent of the two
nonsteroidal agents [32,33], demonstrated the greatest
impact on bone resorption, which continued to be significantly
elevated 3 months after discontinuation of treatment. Thus,
this short-term study suggests there are differences between
steroidal and nonsteroidal AIs; however, the results from this
exploratory, short-term study must be replicated by a larger
controlled trial of longer duration.
The basis for the hypothesized difference in the effects of non-
steroidal AIs and the steroidal aromatase inactivator exemes-
tane is the steroidal structure of exemestane and the
androgenic activity of its primary metabolite, 17-hydroexemes-
tane [18]. Both androgens and estrogens have a role in
skeletal development and maintenance in women [27]. How-
ever, estrogens reduce bone resorption, whereas androgens
stimulate bone formation and are thought to be effective in
reducing fracture risk [34]. In fact, regardless of estrogen sta-
tus, perimenopausal women with higher androgen concentra-
tions have a slower rate of bone loss compared with women
who have lower concentrations [35], and administration of low
doses of oral androgen in combination with estrogen results in
higher concentrations of bone-formation markers than
treatment with estrogen alone in postmenopausal women
[36]. On the basis of its pharmacologic characteristics, these
findings support the hypothesis that exemestane might have
differential effects on bone compared with nonsteroidal AIs.
When the bone-marker data were analyzed for the mITT pop-
ulation (data not shown), the results were similar to those
observed in the evaluable population. The mITT population
included all subjects who received at least one dose of study
medication and had baseline and week 12 assessments at
least. Therefore, unlike the evaluable population, the mITT pop-
ulation included the five patients who did not demonstrate
estrogen suppression following treatment with an AI. Because
third-generation AIs provide consistent suppression ofBreast Cancer Research    Vol 9 No 4    Goss et al.
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estrogen synthesis in postmenopausal women, it is our
impression that these five subjects had poor or inconsistent
compliance and were, therefore, not evaluable for the purpose
of our study because our analysis was designed to demon-
strate the potentially unique response of bone biomarkers to
AIs in the presence of effective suppression of estrogens.
We did not report the BMD or fracture rate because of the rel-
atively short duration of our study. BMD is directly related to
fracture risk and, therefore, often used to diagnose
osteoporosis. However, the BMD must be monitored for sev-
eral years, not months, to be useful for determination of frac-
ture risk, and changes in BMD do not correlate linearly to
fracture risk reduction. Moreover, BMD is only one factor con-
tributing to bone strength and fracture risk. Bone strength is
determined by bone quantity (that is to say, density and size)
and bone quality (that is to say, microarchitecture and mac-
roarchitecture, material properties, and turnover) [37]. In
mechanical terms, the load-bearing capacity or quality of bone
is determined by ultimate force (strength), resilience, stiffness,
and toughness, and the overall quality of bone is affected by
the rate of bone turnover [38]. Although BMD is considered a
good diagnostic tool for identifying osteoporosis in untreated
patients, emerging data suggest that biochemical markers of
bone turnover might also be accurate predictors of treatment-
induced bone changes [37,38].
Ultimately, adverse effects on bone metabolism are among the
most serious concerns when considering the long-term use of
AIs in postmenopausal women. Although measures such as
exercise, calcium and vitamin D supplementation, and
bisphosphonate administration are being used to alleviate this
risk, a finding that exemestane might be superior to other third-
generation AIs, in terms of its effects on bone metabolism,
could have clinical significance. For this reason, two large
ongoing trials are of particular interest: the CAN-NCIC-MA27
study and its companion study, evaluating BMD in postmeno-
pausal women who have primary breast cancer that is treated
using exemestane or anastrozole, and the Femara Anastrozole
Clinical Evaluation study, a comparison of letrozole with anas-
trozole in the treatment of postmenopausal women with hor-
mone-receptor-positive and node-positive breast cancer.
These studies should help determine the relative differences in
the risk of bone loss with long-term use of the different AIs.
Our data support the hypothesis that a mild androgenic effect
on bone can be exerted by the steroidal AI exemestane. Our
study shows a qualitative difference in the concentration of the
bone-formation marker PINP in a short-term, 24-week treat-
ment period, but it involved a small number of women and
these findings need confirmation by a larger trial. It is also
important to note that all AIs are associated with bone loss,
and only long-term comparative clinical studies monitoring
fracture outcome will determine the relative effects of the dif-
ferent AIs on fracture risk. Changes in the levels of bone-
resorption markers are more sensitive in predicting subse-
quent fracture risk than changes in the levels of bone-forma-
tion markers, thus limiting the interpretation of our short-term
findings [39].
However, because androgens affect bone quality and quantity
[40,41], the use of surrogate markers, such as BMD, to assess
bone effects of AIs might not provide a clear indication of com-
parative fracture risk. Bone-quality studies using bone biop-
sies and histomorphometry might prove valuable for assessing
the early effects of exemestane on bone quality.
Conclusion
In recent years, use of the third-generation AIs anastrozole,
letrozole, and exemestane has resulted in improved clinical
outcomes for postmenopausal patients with early breast can-
cer. However, because of their estrogen-lowering effect, AIs
might increase the risk of osteoporosis and fractures in some
patients. Preclinical studies have suggested that exemestane
(a steroidal aromatase inactivator) might have differential
effects on bone compared with the nonsteroidal AIs anastro-
zole and letrozole. In our study, exemestane was the only AI
that significantly increased serum levels of PINP, a marker of
bone formation, at 24 weeks in healthy postmenopausal
women. These data need confirmation by a larger comparative
trial. Whether these observations correlate to a decreased rel-
ative risk of osteoporosis and fractures compared with nons-
teroidal AIs in patients receiving long-term adjuvant treatment
for early breast cancer requires further study.
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